Prostacyclin in vascular diseases - Recent insights and future perspectives

Circulation Journal

Volumn 74, Issue 5, 2010, Pages 836-843

  Kawabe, Jun ichi ^a   Ushikubi, Fumitaka ^a   Hasebe, Naoyuki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Atherosclerosis; Cyclooxygenase; Endothelial progenitor cells; Prostacyclin

Indexed keywords

BERAPROST; CICAPROST; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ILOPROST; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; THROMBOXANE A2;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTERY THROMBOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; DRUG MECHANISM; ENDOTHELIUM CELL; GASTROINTESTINAL TOXICITY; HOMEOSTASIS; HUMAN; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STEM CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITORS; ENDOTHELIAL CELLS; EPOPROSTENOL; HOMEOSTASIS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; STEM CELLS; THROMBOSIS;

EID: 77951755914     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0195     Document Type: Review

References (86)

1. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 2002; 68/69: 165-175.
2. Hinz B, Brune K. Cyclooxygenase-2: 10 years later. J Pharmacol Exp Ther 2002; 300: 367-375.
3. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
4. Helliwell RJ, Adams LF, Mitchell MD. Prostaglandin synthases: Recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 101-113.
5. Ueno N, Takegoshi Y, Kamei D, Kudo I, Murakami M. Coupling between cyclooxygenases and terminal prostanoid synthases. Biochem Biophys Res Commun 2005; 338: 70-76.
6. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al. Role of prostacyclin in the cardiovascular response to thromboxane A 2. Science 2002; 296: 539-541.
7. Smyth EM, FitzGerald GA. Human prostacyclin receptor. Vitam Horm 2002; 65: 149-165.
8. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: Structures, properties, and functions. Physiol Rev 1999; 79: 1193-1226.
9. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007; 115: 518-533.
10. Takano H, Komuro I. Peroxisome proliferator-activated receptor gamma and cardiovascular diseases. Circ J 2009; 73: 214-220.
11. Lim H, Dey SK. A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology 2002; 143: 3207-3210.
12. Zhang J, Fu M, Zhu X, Xiao Y, Mou Y, Zheng H, et al. Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J Biol Chem 2002; 277: 11505-11512.
13. Lim HJ, Lee S, Park JH, Lee KS, Choi HE, Chung KS, et al. PPAR delta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle. Atherosclerosis 2009; 202: 446-454.
14. Pola R, Gaetani E, Flex A, Aprahamian TR, Bosch-Marce M, Losordo DW, et al. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: A possible role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol 2004; 36: 363-370.
15. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, et al. Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27: 63-69.
16. Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, Wu KK. Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 2006; 26: 1481-1487.
17. Tsai MC, Chen L, Zhou J, Tang Z, Hsu TF, Wang Y, et al. Shear stress induces synthetic-to-contractile phenotypic modulation in smooth muscle cells via peroxisome proliferator-activated receptor alpha/delta activations by prostacyclin released by sheared endothelial cells. Circ Res 2009; 105: 471-480.
18. Vila L. Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: Role in atherosclerosis. Med Res Rev 2004; 24: 399-424.
19. Reiss AB, Edelman SD. Recent insights into the role of prostanoids in atherosclerotic vascular disease. Curr Vasc Pharmacol 2006; 4: 395-408.
20. Isogaya M, Yamada N, Koike H, Ueno Y, Kumagai H, Ochi Y, et al. Inhibition of resteNOSis by beraprost sodium (a prostaglandin I2 analogue) in the atherosclerotic rabbit artery after angioplasty. J Cardiovasc Pharmacol 1995; 25: 947-952.
21. Numaguchi Y, Naruse K, Harada M, Osanai H, Mokuno S, Murase K, et al. Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol 1999; 19: 727-733.
22. Arehart E, Stitham J, Asselbergs FW, Douville K, MacKenzie T, Fetalvero KM, et al. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: Potential implications for cyclooxygenase-2 inhibition. Circ Res 2008; 102: 986-993.
23. Bunting S, Gryglewski R, Moncada S, Vane JR. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins 1976; 12: 897-913.
24. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto, Y, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388: 678-682.
25. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004; 306: 1954-1957.
26. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114: 784-794.
27. Thomas DW, Mannon RB, Mannon PJ, Latour A, Oliver JA, Hoffman M, et al. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A. J Clin Invest 1998; 102: 1994-2001.
28. Dogne JM, Hanson J, Pratico D. Thromboxane, prostacyclin and isoprostanes: Therapeutic targets in atherogenesis. Trends Pharmacol Sci 2005; 26: 639-644.
29. Gleim S, Kasza Z, Martin K, Hwa J. Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease. Curr Atheroscler Rep 2009; 11: 227-235.
30. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-3232.
31. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: A reappraisal. Arthritis Rheum 2003; 48: 12-20.
32. Fosslien E. Cardiovascular complications of non-steroidal antiinflammatory drugs. Ann Clin Lab Sci 2005; 35: 347-385.
33. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2: 879-890.
34. Flavahan NA. Balancing prostanoid activity in the human vascular system. Trends Pharmacol Sci 2007; 28: 106-110.
35. FitzGerald GA, Patrono C. The COXibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-442.
36. Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 646-655.
37. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-1291.
38. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 1996; 93: 10417-10422.
39. Smith LH, Boutaud O, Breyer M, Morrow JD, Oates JA, Vaughan DE. Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro. Arterioscler Thromb Vasc Biol 2002; 22: 983-988.
40. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: Selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001; 167: 2831-2838.
41. Cook-Johnson RJ, Demasi M, Cleland LG, Gamble JR, Saint DA, James MJ. Endothelial cell COX-2 expression and activity in hypoxia. Biochim Biophys Acta 2006; 1761: 1443-1449.
42. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-845.
43. Yamada M, Numaguchi Y, Okumura K, Harada M, Naruse K, Matsui H, et al. Prostacyclin synthase gene transfer modulates cyclooxygenase-2-derived prostanoid synthesis and inhibits neointimal formation in rat balloon-injured arteries. Arterioscler Thromb Vasc Biol 2002; 22: 256-262.
44. Hansson GK, Libby P. The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol 2006; 6: 508-519.
45. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 2001; 104: 921-927.
46. Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 246-255.
47. Cipollone F, Fazia M, Mezzetti A. Novel determinants of plaque instability. J Thromb Haemost 2005; 3: 1962-1975.
48. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002; 105: 1816-1823.
49. Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hla T. Induction of cyclooxygenase-2 by interleukin-1 alpha: Evidence for post-transcriptional regulation. J Biol Chem 1994; 269: 11769-11775.
50. Arias-Negrete S, Keller K, Chadee K. Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. Biochem Biophys Res Commun 1995; 208: 582-589.
51. Belton O, Fitzgerald D. Cyclooxygenase-2 inhibitors and atherosclerosis. J Am Coll Cardiol 2003; 41: 1820-1822.
52. Yatomi Y, Ozaki Y, Ohmori T, Igarashi Y. Sphingosine 1-phosphate: Synthesis and release. Prostaglandins 2001; 64: 107-122.
53. 2+dependent, but MAPK-independent mechanism in rat vascular smooth muscle cells. Life Sci 2007; 80: 1768-1776.
54. Rodriguez C, Gonzalez-Diez M, Badimon L, Martinez-Gonzalez J. Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb Haemost 2009; 101: 665-673.
55. Rolland PH, Jouve R, Pellegrin E, Mercier C, Serradimigni A. Alteration in prostacyclin and prostaglandin E2 production: Correlation with changes in human aortic atherosclerotic disease. Arteriosclerosis 1984; 4: 70-78.
56. Kainoh M, Maruyama I, Nishio S, Nakadate T. Enhancement by beraprost sodium, a stable analogue of prostacyclin, in thrombomodulin expression on membrane surface of cultured vascular endothelial cells via increase in cyclic AMP level. Biochem Pharmacol 1991; 41: 1135-1140.
57. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-1311.
58. Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, et al. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 2002; 62: 63-66.
59. Hoper MM, Voelkel NF, Bates TO, Allard JD, Horan M, Shepherd D, et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol 1997; 17: 748-756.
60. Pueyo ME, Chen Y, D'Angelo G, Michel JB. Regulation of vascular endothelial growth factor expression by cAMP in rat aortic smooth muscle cells. Exp Cell Res 1998; 238: 354-358.
61. Smith OP, Battersby S, Sales KJ, Critchley HO, Jabbour HN. Prostacyclin receptor up-regulates the expression of angiogenic genes in human endometrium via cross talk with epidermal growth factor Receptor and the extracellular signaling receptor kinase 1/2 pathway. Endocrinology 2006; 147: 1697-1705.
62. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998; 97: 99-107.
63. Hiraoka K, Koike H, Yamamoto S, Tomita N, Yokoyama C, Tanabe T, et al. Enhanced therapeutic angiogenesis by cotransfection of prostacyclin synthase gene or optimization of intramuscular injection of naked plasmid DNA. Circulation 2003; 108: 2689-2696.
64. Koike H, Morishita R, Iguchi S, Aoki M, Matsumoto K, Nakamura T, et al. Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene. Faseb J 2003; 17: 779-781.
65. Wheeler-Jones C, Abu-Ghazaleh R, Cospedal R, Houliston RA, Martin J, Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett 1997; 420: 28-32.
66. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 1999; 274: 25130-25135.
67. Krishnamurthy P, Bird IM, ShePPARd C, Magness RR. Effects of angiogenic growth factors on endothelium-derived prostacyclin production by ovine uterine and placental arteries. Prostaglandins Other Lipid Mediat 1999; 57: 1-12.
68. Matsumoto K, Morishita R, Tomita N, Moriguchi A, Yamasaki K, Aoki M, et al. Impaired endothelial dysfunction in diabetes mellitus rats was restored by oral administration of prostaglandin I2 analogue. J Endocrinol 2002; 175: 217-223.
69. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411-418.
70. Niwano K, Arai M, Tomaru K, Uchiyama T, Ohyama Y, Kurabayashi M. Transcriptional stimulation of the eNOS gene by the stable prostacyclin analogue beraprost is mediated through cAMP-responsive element in vascular endothelial cells: Close link between PGI2 signal and NO pathways. Circ Res 2003; 93: 523-530.
71. Niwano K, Arai M, Koitabashi N, Hara S, Watanabe A, Sekiguchi K, et al. Competitive binding of CREB and ATF2 to cAMP/ATF responsive element regulates eNOS gene expression in endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26: 1036-1042.
72. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
73. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, et al. Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105: 3017-3024.
74. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003; 93: e17-e24.
75. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5: 434-438.
76. Takakura N, Watanabe T, Suenobu S, Yamada Y, Noda T, Ito Y, et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 2000; 102: 199-209.
77. Miyahara Y, Ohnishi S, Obata H, Ishino K, Sano S, Mori H, et al. Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats. Biochem Biophys Res Commun 2006; 349: 1242-1249.
78. Otsuka H, Akashi H, Murohara T, Okazaki T, Shintani S, Tayama K, et al. The prostacyclin analog beraprost sodium augments the efficacy of therapeutic angiogenesis induced by autologous bone marrow cells. Ann Vasc Surg 2006; 20: 646-652.
79. Di Stefano R, Barsotti MC, Melillo E, Iorio M, Santoni T, Armani C, et al. The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia. Thromb Haemost 2008; 100: 871-877.
80. Asai J, Takenaka H, Katoh N, Kishimoto S. Dibutyryl cAMP influences endothelial progenitor cell recruitment during wound neovascularization. J Invest Dermatol 2006; 126: 1159-1167.
81. He T, Lu T, d'Uscio LV, Lam CF, Lee HC, Katusic ZS. Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. Circ Res 2008; 103: 80-88.
82. Kawabe JI, Yuhki KI, Okada M, Kanno T, Yamauchi A, Tashiro, N, et al. Prostaglandin I2 promotes recruitment of endothelial progenitor cells and limits vascular remodeling. Arterioscler Thromb Vasc Biol 2010; 30: 464-470.
83. Sainz J, Sata M. When endothelial progenitor cell says I2 shall limit neiointima formation! Arterioscler Thromb Vasc Biol 2010; 30: 457-458.
84. He T, Peterson TE, Katusic ZS. Paracrine mitogenic effect of human endothelial progenitor cells: Role of interleukin-8. Am J Physiol Heart Circ Physiol 2005; 289: H968-H972.
85. Santhanam AV, Smith LA, He T, Nath KA, Katusic ZS. Endothelial progenitor cells stimulate cerebrovascular production of prostacyclin by paracrine activation of cyclooxygenase-2. Circ Res 2007; 100: 1379-1388.
86. Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007; 49: 741-752.